Skip to content

Rehabilitation Exercise With MObile Technology and Education After Acute Coronary Syndrome

Is Tele-rehabilitation an Efficacious Alternative to Traditional Center Based Cardiac Rehabilitation After Acute Coronary Syndrome?

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05385341
Acronym
REMOTE-ACS
Enrollment
0
Registered
2022-05-23
Start date
2024-12-01
Completion date
2025-12-31
Last updated
2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Cardiac rehabilitation, Tele-health

Brief summary

Despite a clear indication of grade Ia, cardiac rehabilitation (CR) is dramatically underutilized after acute coronary syndrome with less than 30% of patients addressed in France. Mobile technology has the potential to overcome barriers to access to cardiac rehabilitation and may be a useful tool for increasing participation. However, studies have to prove this type of care is as effective as traditional center based cardiac rehabilitation.

Detailed description

After acute coronary syndrome (ACS), it is recommended to propose a cardiac rehabilitation (CR) program in order to reduce the risk of recidive, to improve the quality of life and to reduce the risk of disabilities. Traditional CR which is most of the time center-based, is underutilized with less than 30% of patients addressed en France. Therefore, Télé-Cardiac Rehabilitation (Télé-RCV) has been developped progressively since the eighties showing comparable efficacity compared with CR concerning physical fitness. The investigative team, had previously published results showing that telephone support guided by accelerometers could improve physical activity. However, In France, device allowing telemonitoring online of heart rate are not available. Moreover, the investigators have not yet developped remote therapeutic education which is proposed in CR programs. Thus, the present study planned to develop and evaluate aTele-RCV solution aimed to monitor exercise training at home and to educate remotely patient after ACS. The device is an association of a heart rate monitor, a blood pressure testing, a balance linked with a full web secured application connecting patient and caregivers. In the intervention group, Tele-RCV is proposed during 20 sessions containing 2h of exercise training combined with 6h of therapeutic tele-education. In the control group, CR is proposed during 20 sessions with the same volume of exercise training and therapeutic education. After randomisation, patient are allocated to one of the two groups. The evaluation of the primary and secondary outcomes are realized at the beginning, at one month (only walking tests) and at 2 months. A social evaluation is done in parallel to test the acceptability for the Télé-RCV compared with CR.

Interventions

OTHERTelerehabilitation (Tele RCV)

20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training associated with educative sessions.

OTHERRehabilitation (RCV)

20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Patient with acute coronary syndrome less than 6 months, * Addressed to ambulatory cardiac rehabilitation, * Equipped with a smartphone compatible with the protocol's application, connected to web * Having signed an informed consent, * Affiliated to the french national health insurance.

Exclusion criteria

* Incapacity to use application on smartphone, * Contraindication to exercise training, * Pregnancy, * Juridic protection * Left ventricular ejection fraction \< 45% * Significate ventricular arrhythmia (frequent or polymorph PVC during initial exercise testing, ventricular tachycardia or sudden cardiac death at the beginning) * Flutter or atrial fibrillation (transient or permanent) * Coronary revascularization needing supplementary procedure * Residual myocardial ischemia determined by initial exercise testing or alternative testing (nuclear imaging or stress echocardiography) * Mini Mental State \< 26 * Patients living alone at home * Comorbidities limiting participation to the protocol: kidney dialysis, insulin-requiring diabetes, residuals sequels of central and/or peripheral nervous system injuries

Design outcomes

Primary

MeasureTime frameDescription
Effect analysis 2 month after inclusion2 monthsChange of the peak oxygen volume at 2 months after inclusion

Secondary

MeasureTime frameDescription
Effect analysis 1 month after inclusion1 monthAnalysis of change between T0 and 1 month concerning the walking tests : distance traveled in meters
Effect analysis 2 months after inclusion2 monthsAnalysis of change between T0 and 2 months concerning the walking tests:distance traveled in meters
Health economics criteria26 monthsIncremental Cost-effectiveness ratios of the REMOTE-ACS device compared with the traditional cardiac rehabilitation after acute coronary syndrome according to the French national health insurance perspective and 2 months follow-up period.
Production cost of the REMOTE-ACS device26 monthsProduction cost of the REMOTE-ACS device by micro costing, according the hospital perspective
Acceptability of the device26 monthsThe acceptability will be assessed by a sociological point of view based on collective meeting (with patient and caregivers) and individual questionnaires for the two groups before randomization and after the program only for the Tele-RCV group.
Satisfaction of the device26 monthsThe satisfaction will be assessed by a questionnaire of satisfaction titled: Cardiovascular rehabilitation program satisfaction questionnaire, with 8 questions, the minimum value is "nothing", and the maximum value is "very important"

Contacts

PRINCIPAL_INVESTIGATORMeyer ELBAZ, MD

University Hospital, Toulouse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026